SVCM
CABA icon

Saturn V Capital Management’s Cabaletta Bio CABA Stock Holding History

Saturn V Capital Management’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-173,173
Closed -$2.95M – 28
2024
Q1 		$2.95M Buy
+173,173
New +$3.72M 1.18% 21

Other funds holding CABA

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Saturn V Capital Management's CABA Position: Q2 2024 in Review

Saturn V Capital Management sold out of Cabaletta Bio (CABA) in Q2 2024, closing a stake of 173,173 shares — an estimated $2.95M sold.

Saturn V Capital Management first reported a position in CABA in Q1 2024 and held it in 1 quarter. The position peaked at $2.95M in Q1 2024. 142 funds tracked by Wall St. Rank hold CABA as of Q2 2024.

  • Saturn V Capital Management reported no remaining Cabaletta Bio position as of Q2 2024 after selling out during the quarter.
  • Saturn V Capital Management sold 173,173 Cabaletta Bio shares in Q2 2024, an estimated $2.95M.
  • Saturn V Capital Management first reported a position in Cabaletta Bio in Q1 2024 and held it in 1 quarter.
  • Saturn V Capital Management's Cabaletta Bio position peaked at $2.95M in Q1 2024.
  • 142 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2024.

Based on Saturn V Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.